Choong-wae, Sanwa to develop SK-0403 for treatment of diabetes
Published: 2008-08-27 06:53:00
Updated: 2008-08-27 06:53:00
Choong-wae Pharm has entered into an exclusive licensing agreement with Sanwa Kagaku Kenkyusho Co., Ltd. (Sanwa) to develop and commercialize SK-0403 (dipeptidyl peptidase-IV inhibitor) for treatment of diabetes, according to a Choong-wae official.
The companies currently estimate Korea's annu...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
